| 王蕾，程晓波▲，朱双明，杨莉，胡志伟.肝动脉灌注化疗联合瑞戈非尼治疗结直肠癌肝转移患者的效果评价[J].中国医药科学,2025,(6):105-108转155 基金项目:卫生健康发展促进项目—助力国家公立医院科研能力提升公益项目（KM-ZLGJ-003） |
| 肝动脉灌注化疗联合瑞戈非尼治疗结直肠癌肝转移患者的效果评价 |
| Evaluation of the effect of hepatic arterial infusion chemotherapy combined with Regorafenib in the treatment of patients with colorectal cancer liver metastasis |
| |
| DOI： |
| 中文关键词: 肝动脉灌注化疗；瑞戈非尼；结直肠癌肝转移；肿瘤标志物；肝功能 |
| 英文关键词:Hepatic arterial infusion chemotherapy; Regorafenib; Colorectal cancer liver metastasis; Tumor markers; Hepatic function |
| 作者 | 单位 | | 王蕾，程晓波▲，朱双明，杨莉，胡志伟 | 湖北省当阳市人民医院肿瘤科，湖北当阳 444100 |
|
| 摘要点击次数: 29 |
| 全文下载次数: 34 |
| 中文摘要: |
| [摘要] 目的 评估肝动脉灌注化疗（HAIC）+瑞戈非尼应用在结直肠癌肝转移（CRLM）患者中的效果。 方法 纳入2022年1月至2023年12月湖北省当阳市人民医院的60例CRLM患者，按照治疗方法分组，对照组30例（HAIC）、观察组30例（HAIC+瑞戈非尼）。评价两组临床有效率、肝功能、肿瘤标志物、药品不良反应（ADR）。 结果 治疗28 d后，观察组疾病控制率、客观缓解率均高于对照组，丙氨酸转氨酶、天冬氨酸转氨酶、糖类抗原125（CA125）、糖类抗原199（CA199）、癌胚抗原均低于对照组，差异有统计学意义（P < 0.05）。两组ADR比较，差异无统计学意义（P > 0.05）。 结论 对CRLM患者采用HAIC+瑞戈非尼方案，可以提高近期疗效，改善肝功能，降低CA125、CA199等肿瘤标志物表达，不良反应可控。 |
| 英文摘要: |
| [Abstract] Objective To evaluate the effect of hepatic arterial infusion chemotherapy (HAIC) combined with Regorafenib in the treatment of patients with colorectal cancer liver metastasis (CRLM). Methods A total of 60 patients with CRLM admitted to Dangyang People’s Hospital from January 2022 to December 2023 were included and divided into the control group (n=30, with HAIC) and the observation group (n=30, with HAIC combined with Regorafenib) according to treatment methods. The clinical response rate, hepatic function, tumor markers and adverse drug reactions (ADR) between the two groups were evaluated. Results After 28 days of treatment, the disease control rates and objective remission rates in the observation group were all higher than those in the control group, while alanine aminotransferase, aspartate aminotransferase, carbohydrate antigen 125 (CA125), carbohydrate antigen 199 (CA199) and carcinoembryonic antigen were lower than those in the control group, with statistically significant differences (P < 0.05). There was no statistically significant difference in ADR between the two groups (P > 0.05). Conclusion Using HAIC+ Regorafenib regimen for CRLM patients can improve the short-term therapeutic efficacy, improve the hepatic function and reduce the expression of tumor markers such as CA125 and CA199, and the ADRs can be controlled. |
| 查看全文 查看/发表评论 下载PDF阅读器 |
| 关闭 |
.jpg)